DR4 is a common risk allele between RA and T1D (28) and is associated with better outcome in a clinical trial of teplizumab (anti-CD3) therapy in individuals at risk for T1D (15). The gene discussed is TNFRSF10A; the disease is rheumatoid arthritis.